Biomarkers

Serum tumor-derived cfDNA mutations on PI3KCA could help predict survival in breast cancer patients receiving Ibrance palbociclib and Faslodex fulvestrant. In 52 patients treated with a combination of Ibrance and Faslodex, high frequencies in serum tumor-derived cfDNA of one or more PI3KCA mutations -- E542K, H1047R, H1047L and E545K -- were associated with poor progression-free survival. Next steps could include validating the biomarkers in larger patient cohorts.

Pfizer Inc. and Amgen Inc. market Ibrance, an oral small molecule cyclin dependent kinase 4 (CDK4) and CDK6 inhibitor, to treat breast cancer and have the compound in Phase II testing to treat oligodendroglioma, sarcoma, and head and neck cancer and in preclinical testing to treat melanoma...